Joon Young Hur1, Bo Mi Ku2, Joon Ho Shim3,4, Hyun Ae Jung1, Jong-Mu Sun1, Se-Hoon Lee1, Jin Seok Ahn1, Keunchil Park1, Myung-Ju Ahn5. 1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2. Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 3. Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea. 4. Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 5. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea silkahn@skku.edu silk.ahn@samsung.com.
Abstract
BACKGROUND/AIM: MET exon 14 skipping occurs in 3-4% of patients with lung adenocarcinomas. In this study, we performed a comprehensive analysis of clinical data from Korean non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping. PATIENTS AND METHODS: Overall, 1,020 patients diagnosed with NSCLC between January 2015 and July 2017 were analyzed by next-generation sequencing. RESULTS: MET exon 14 skipping was identified in 20 NSCLC patients (1.9%). The median age was 69 years (range=39-86 years), 60.0% were male, and most (55.0%) were ever-smokers. For first-line chemotherapy, the median overall survival was 9.5 months and progression-free survival was 4.0 months, respectively. Twelve patients received pemetrexed-based chemotherapy and the overall response rate was 33.3% (4/12). Among four crizotinib-treated patients, one continued therapy for 8 months with the best response being disease stability. CONCLUSION: Given the poor clinical outcome and response to therapy for NSCLC, and the availability of promising anti-tumor MET inhibitors, screening for the MET exon 14 skip mutation should be incorporated into clinical practice. Copyright
BACKGROUND/AIM: MET exon 14 skipping occurs in 3-4% of patients with lung adenocarcinomas. In this study, we performed a comprehensive analysis of clinical data from Korean non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping. PATIENTS AND METHODS: Overall, 1,020 patients diagnosed with NSCLC between January 2015 and July 2017 were analyzed by next-generation sequencing. RESULTS:MET exon 14 skipping was identified in 20 NSCLCpatients (1.9%). The median age was 69 years (range=39-86 years), 60.0% were male, and most (55.0%) were ever-smokers. For first-line chemotherapy, the median overall survival was 9.5 months and progression-free survival was 4.0 months, respectively. Twelve patients received pemetrexed-based chemotherapy and the overall response rate was 33.3% (4/12). Among four crizotinib-treated patients, one continued therapy for 8 months with the best response being disease stability. CONCLUSION: Given the poor clinical outcome and response to therapy for NSCLC, and the availability of promising anti-tumorMET inhibitors, screening for the MET exon 14 skip mutation should be incorporated into clinical practice. Copyright
Authors: Jie Qi; Michele A McTigue; Andrew Rogers; Eugene Lifshits; James G Christensen; Pasi A Jänne; Jeffrey A Engelman Journal: Cancer Res Date: 2011-01-25 Impact factor: 12.701
Authors: Sai-Hong Ignatius Ou; Eunice L Kwak; Christina Siwak-Tapp; Joni Dy; Kristin Bergethon; Jeffrey W Clark; D Ross Camidge; Benjamin J Solomon; Robert G Maki; Yung-Jue Bang; Dong-Wan Kim; James Christensen; Weiwei Tan; Keith D Wilner; Ravi Salgia; A John Iafrate Journal: J Thorac Oncol Date: 2011-05 Impact factor: 15.609
Authors: Magda Bahcall; Mark M Awad; Lynette M Sholl; Frederick H Wilson; Man Xu; Stephen Wang; Sangeetha Palakurthi; Jihyun Choi; Elena V Ivanova; Giulia C Leonardi; Bryan C Ulrich; Cloud P Paweletz; Paul T Kirschmeier; Masayuki Watanabe; Hideo Baba; Mizuki Nishino; Rebecca J Nagy; Richard B Lanman; Marzia Capelletti; Emily S Chambers; Amanda J Redig; Paul A VanderLaan; Daniel B Costa; Yu Imamura; Pasi A Jänne Journal: Clin Cancer Res Date: 2018-08-02 Impact factor: 12.531
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Parneet K Cheema; Shantanu O Banerji; Normand Blais; Quincy S-C Chu; Patrice Desmeules; Rosalyn A Juergens; Natasha B Leighl; Brandon S Sheffield; Paul F Wheatley-Price; Barbara L Melosky Journal: Curr Oncol Date: 2021-11-09 Impact factor: 3.677
Authors: Marisa Bittoni; James Chih-Hsin Yang; Jin-Yuan Shih; Nir Peled; Egbert F Smit; D Ross Camidge; Rajeswara Rao Arasada; Dina Oksen; Emmanuelle Boutmy; Christopher Stroh; Andreas Johne; David P Carbone; Paul K Paik Journal: Lung Cancer Date: 2021-07-16 Impact factor: 6.081